Genome editing efficiency was 38.6% and 33.4% in difficult-to-transfect HepG2 cells in vitro and in tumor tissues in vivo, respectively, with more than 60% reduction in VEGFR2 protein expression and 70% tumor growth suppression in mice (Figure 1C) (26). The gene discussed is KDR; the disease is neoplasm.